BWAY
Brainsway Ltd
$
14.990
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
15.100
Open
15.030
VWAP
14.96
Vol
115.93K
Mkt Cap
566.68M
Low
14.5168
Amount
1.73M
EV/EBITDA(TTM)
53.71
Total Shares
16.66M
EV
204.31M
EV/OCF(TTM)
8.82
P/S(TTM)
6.65
Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
12.91M
+22.88%
--
--
13.62M
+19.3%
--
--
13.80M
+19.63%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for BrainsWay Ltd. (BWAY) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 44.13%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+44.13%
In Past 3 Month
4 Analyst Rating
-1.60% Downside
Wall Street analysts forecast BWAY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BWAY is 14.75 USD with a low forecast of 13.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
-1.60% Downside
Current: 14.990
Low
13.00
Averages
14.75
High
16.00
-1.60% Downside
Current: 14.990
Low
13.00
Averages
14.75
High
16.00
H.C. Wainwright
Buy
upgrade
$16 -> $17
2025-08-14
Reason
H.C. Wainwright
Price Target
$16 -> $17
2025-08-14
upgrade
Buy
Reason
H.C. Wainwright raised the firm's price target on Brainsway to $17 from $16 and keeps a Buy rating on the shares. The firm expects accelerating growth for Brainsway in the coming quarters following the in-line Q2 report.
Northland
Outperform
upgrade
$15 -> $19
2025-08-14
Reason
Northland
Price Target
$15 -> $19
2025-08-14
upgrade
Outperform
Reason
Northland raised the firm's price target on Brainsway to $19 from $15 and keeps an Outperform rating on the shares. BrainsWay beat expectations in Q2 and fundamentals "continue to strengthen," the analyst tells investors in a post-earnings note.
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$16
2025-03-12
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$16
2025-03-12
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$16
2024-12-23
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$16
2024-12-23
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$16
2024-10-21
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$16
2024-10-21
Reiterates
Strong Buy
Reason
Northland Capital Markets
Carl Byrnes
Buy
Maintains
$11 → $13
2024-10-03
Reason
Northland Capital Markets
Carl Byrnes
Price Target
$11 → $13
2024-10-03
Maintains
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Brainsway Ltd (BWAY.O) is 81.52, compared to its 5-year average forward P/E of 31.69. For a more detailed relative valuation and DCF analysis to assess Brainsway Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
31.69
Current PE
81.52
Overvalued PE
119.66
Undervalued PE
-56.28
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-4.99
Current EV/EBITDA
22.87
Overvalued EV/EBITDA
6.41
Undervalued EV/EBITDA
-16.39
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Overvalued
5Y Average PS
3.08
Current PS
5.04
Overvalued PS
4.39
Undervalued PS
1.77
Financials
Annual
Quarterly
FY2025Q1
YoY :
+26.84%
11.54M
Total Revenue
FY2025Q1
YoY :
+519.35%
576.00K
Operating Profit
FY2025Q1
YoY :
+897.30%
1.11M
Net Income after Tax
FY2025Q1
0.02
EPS - Diluted
FY2025Q1
YoY :
+61.65%
3.97M
Free Cash Flow
FY2025Q1
YoY :
-0.35%
74.64
Gross Profit Margin - %
FY2025Q1
YoY :
+29.20%
18.45
FCF Margin - %
FY2025Q1
YoY :
+686.89%
9.60
Net Margin - %
FY2025Q1
7.13
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
BWAY News & Events
Events Timeline
2025-08-21 (ET)
2025-08-21
07:39:02
Brainsway finalizes $5M strategic loan investment in Neurolief
2025-08-20 (ET)
2025-08-20
07:34:18
Brainsway Purchases Minority Stake in Axis Integrated Mental Health
2025-08-13 (ET)
2025-08-13
07:39:25
Brainsway sees FY25 revenue $50M-$52M, consensus $50.1M
Sign Up For More Events
Sign Up For More Events
News
8.5
08-21NewsfilterPinnedBrainsWay Aims to Broaden Its Market Reach with Strategic Investment in Neuromodulation Systems Firm Neurolief Ltd.
8.5
08-20NewsfilterPinnedBrainsWay Purchases Minority Stake in Axis Integrated Mental Health
3.0
08-18NASDAQ.COMRising Earnings Projections Indicate Potential Growth for Brainsway (BWAY) Stock
Sign Up For More News
People Also Watch
ETON
Eton Pharmaceuticals Inc
17.090
USD
+3.26%
APEI
American Public Education Inc
31.100
USD
+2.78%
GILT
Gilat Satellite Networks Ltd
9.510
USD
+6.85%
FBIZ
First Business Financial Services Inc
49.340
USD
-0.90%
OOMA
Ooma Inc
11.640
USD
+1.04%
BRY
Berry Corporation (Bry)
2.840
USD
+1.43%
WOW
WideOpenWest Inc
5.080
USD
0.00%
ALLO
Allogene Therapeutics Inc
1.120
USD
+5.66%
CRMT
America's CAR-MART Inc
44.680
USD
+0.69%
FAQ
What is Brainsway Ltd (BWAY) stock price today?
The current price of BWAY is 14.99 USD — it has increased 1.49 % in the last trading day.
What is Brainsway Ltd (BWAY)'s business?
What is the price predicton of BWAY Stock?
What is Brainsway Ltd (BWAY)'s revenue for the last quarter?
What is Brainsway Ltd (BWAY)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Brainsway Ltd (BWAY)'s fundamentals?
How many employees does Brainsway Ltd (BWAY). have?